Watson Oxytrol Using "Direct-To-Patient" Promotion In Physician Waiting Room
This article was originally published in The Pink Sheet Daily
Watson expects products from GlaxoSmithKline and Novartis to grow the overactive bladder market in 2005. Before their entry, Watson will have the opportunity to bulk up its sales force through acquisition of sales reps from Ventiv.
You may also be interested in...
FDA clears Vesicare for the treatment of overactive bladder. Yamanouchi and co-promotion partner GlaxoSmithKline will launch solifenacin in January 2005, with GSK sales reps handling primary care duties and Yamanouchi reps detailing to urologist and ob/gyns.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.